Biomarkers and Precision Oncology Forum shared a post on LinkedIn:
“Precision Oncology and Hematology Session – BPOF 2026.
The opening session of BPOF 2026 brings together leading specialists to examine the evolving science of biomarker-driven cancer care — from molecular diagnostics and targeted therapeutics to AI-enabled treatment personalization and cell therapy in solid tumours.
Session Agenda:
- Precision at the Molecular Level: Evolving Landscape of Biomarker Testing
- Targeted Therapeutics in NF1 (selumetinib) and NF2
- Personalization of Chemotherapy with AI
- Cost Barriers in Precision Oncology
- Cell Therapy in Solid Tumour
30 July 2026
Academia, Singapore
09:00 – 10:30 HRS (SGT)
CME Accredited
Because behind every biomarker, there is a patient waiting.
Other articles about BPOF on OncoDaily.